Amgen Inc., Siemens Medical Solutions USA, Inc. ( A Subsidiary of Siemens Healthcare Gmbh), and Koninklijke Philips N.V. Are Dominating North America Bone Metastasis Market In 2020

North America Bone Metastasis Market is expected to grow with a CAGR of 8.4% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-bone-metastasis-market

North America bone metastasis market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.   

The major players dealing in North America bone metastasis market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In April 2021, Amgen Inc. launched Biomarker Assist, a program intended to help more and more patients suffering from non-small cell lung cancer by gaining access to biomarker testing. This initiative allows healthcare professionals to communicate with patients easily and increases their customer engagement.

Amgen Inc. is the dominating player in North America bone metastasis market. The other key players existing in the market are Amgen Inc., Pfizer Inc., Cipla Inc., Dr. Reddy's Laboratories Ltd., Sagent Pharmaceuticals, Inc.  (a subsidiary of Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Accord Healthcare, AuroMedics Pharma LLC (a subsidiary of Aurobindo Pharma), Ingenus Pharmaceutical, Fresenius Kabi AG, Bayer AG, Lantheus Medical Imaging, Inc.  (a subsidiary of Lantheus Holdings, Inc.), Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Genentech, Inc.  (a subsidiary of F. Hoffmann-La Roche Ltd), DAIICHI SANKYO COMPANY, LIMITED, Viatris Inc., GENERAL ELECTRIC COMPANY, Koninklijke Philips N.V., Siemens Medical Solutions USA, Inc. (a subsidiary of Siemens Healthcare GmbH)  among others.

 North America Bone Metastasis MarketAmgen Inc.  

Amgen Inc. is headquartered in California, U.S. The company was founded in the year 1980. The company is focused on the use of science and technology in search of therapies in order to improve the lives of those who suffer from serious diseases. The company is engaged in the manufacturing and marketing of several products, including AMJEVITA, Aimovig, AVSOLA, Enbrel, EPOGEN, KANJINTI, Neulasta, Vectibix, XGEVA, among others in which XGEVA  is the market focused product.

For instance,

  • In April 2021, Amgen Inc. has successfully acquired Five Prime Therapeutics, which includes a tender offer to purchase all outstanding shares of common stock. This has provided the company with an opportunity to boost up its oncology pipeline and enhance its production.

The company has a wide presence across Europe, Asia-Pacific, the Middle East and Africa, Americas. The company also has various subsidiary companies, including Amgen Canada Inc. (Ontario), Amgen (Europe) GmbH (Switzerland), Amgen Manufacturing, Limited (Bermuda), Amgen Rockville, Inc. (Delaware), ATL Holdings Limited (Bermuda), and many more.

Siemens Medical Solutions USA, Inc.  (a subsidiary of Siemens Healthcare GmbH) 

Siemens Medical Solutions USA, Inc.  (a subsidiary of Siemens Healthcare GmbH)  Limited was founded in the year 1982, headquartered in Pennsylvania, U.S. The company is focused in empowering medical providers for precision medicine, transforming care delivery and improving patient experience, and digitalizing healthcare. The company has three product categories, including Medical Imaging, Diagnostics, Advanced Therapies, Services, among which Medical Imaging is the market-focused category.

  • In March 2021, Siemens Medical Solutions USA, Inc. has achieved Food and Drug Administration (FDA) approval for Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner indicated for clinical use as well as translational research. This approval boosted the company's existing product portfolio for cancer diagnosis and allowed it to penetrate its root in the bone metastasis market.

The company has a presence across North America and Europe.

Koninklijke Philips N.V.  

Koninklijke Philips N.V. founded in the year 1891, headquarter in Amsterdam, The Netherlands. The company is engaged in offering diagnostic imaging, patient monitoring, image-guided therapy, and health informatics, and also solutions in consumer health and home care. The company operates its business through several business segments, including diagnosis and treatment businesses, personal health businesses, connected care, and health, among others in which diagnosis and treatment businesses is the market focused segment. The company has two product categories, including consumer care and professional healthcare, among which professional healthcare is the market focused category.

  • In June 2021, Koninklijke Philips N.V. went under a strategic partnership with Elekta. Through this initiative, the company has enhanced the advanced comprehensive and personalized cancer care product portfolio with the involvement of deep oncology solutions to its existing product portfolio. This partnership allowed the company to attain lucrative growth in the bone metastasis market.

The company has a presence across Europe, the Americas, Asia-Pacific, Middle East, and Africa. The company also has various subsidiary companies, including Philips GmbH (Germany), Philips Consumer Lifestyle B.V. (The Netherlands), Philips Medical Systems Nederland B.V. (The Netherlands), Philips Ultrasound, Inc. (U.S.), Philips Oral Healthcare, LLC (U.S.) among others.